Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Edetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.93 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.88 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.88 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.88 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.88 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.88 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.88 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.88 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.88 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.88 |
| ▸ | CA2 known ✓ | P00918 | 15/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.93 |
| ▸ | EYA2 | O00167 | 1/20 | 0.93 |
| ▸ | APP | P05067 | 1/20 | 0.93 |
| ▸ | BLM | P54132 | 2/20 | 0.88 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.88 |
| ▸ | TSHR | P16473 | 2/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.88 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.88 |
| ▸ | LMNA | P02545 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL1720381 | 1.00 | TDP1 (0.93) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL8109408 | 1.00 | TDP1 (0.93) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL3890336 | 0.97 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL7790960 | 0.97 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL1162301 | 0.97 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL8016093 | 0.97 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL4956709 | 0.97 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL8607480 | 0.97 | TDP1 (1.00) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL8624198 | 0.97 | TDP1 (1.00) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL16714076 | 0.97 | TDP1 (1.00) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7155188-A | — | — | None | — | — | JP | disclosed |
| CN-119958939-A | Sperm nucleus integrity detection reagent and preparation and use methods thereof | 沈阳中元宜和生物科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119958939-A | Sperm nucleus integrity detection reagent and preparation and use methods thereof | 沈阳中元宜和生物科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20220184037-A1 | PHARMACEUTICAL AGENTS TARGETING CANCER STEM CELLS | UNIV JOHNS HOPKINS (US) | 2022-06-16 | — | — | US | disclosed |
| US-10888549-B2 | Pharmaceutical agents targeting cancer stem cells | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190091202-A1 | PHARMACEUTICAL AGENTS TARGETING CANCER STEM CELLS | THE JOHNS HOPKINS UNIVERSITY | 2019-03-28 | — | — | US | disclosed |
| US-8586350-B2 | Mechanism of separating and purifying DNA and the like | GL SCIENCES INCORPORATED (JP) | 2013-11-19 | — | — | US | disclosed |
| EP-1719816-B1 | MECHANISM OF SEPARATING AND PURIFYING DNA | GL SCIENCES INC (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-20090035767-A1 | PRIMER FOR BACTERIUM GENOME AMPLIFICATION REACTION | CANON KABUSHIKI KAISHA (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1388588-B1 | Nucleic acid-separating method and nucleic acid-extracting reagent | JSR CORP (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1927664-A1 | Primer for bacterium genome amplification reaction | CANON KABUSHIKI KAISHA (JP) | 2008-06-04 | — | — | EP | disclosed |
| US-20070181482-A1 | Mechanism of separating and purifying dna and the like | GL SCIENCES INCORPORATED (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20060275917-A1 | Method for staining and destaining gel, electrophoresis destaining device for gel, and kit for staining and destaining gel | THE LAB. OF BIO-INFORMATICS TECHNOLOGY (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1719816-A1 | MECHANISM OF SEPARATING AND PURIFYING DNA AND SO ON | Gl Sciences Incorporated (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20040029166-A1 | Nucleic acid-separating method and nucleic acid-extracting reagent | JSR CORPORATION (JP) | 2004-02-12 | — | — | US | disclosed |
| EP-1388588-A1 | Nucleic acid-separating method and nucleic acid-extracting reagent | JSR Corporation (JP) | 2004-02-11 | — | — | EP | disclosed |
| US-5965361-A | In-situ hybridization method using RecA protein and RecA protein having marker or ligand for use in said method | DAIKIN INDUSTRIES, LTD. (JP) | 1999-10-12 | — | — | US | disclosed |
| EP-0687738-A1 | IN-SITU HYBRIDIZATION METHOD USING RecA PROTEIN AND RecA PROTEIN HAVING MARKER OR LIGAND FOR USE IN SAID METHOD | DAIKIN INDUSTRIES, LTD. (JP) | 1995-12-20 | — | — | EP | disclosed |
| JP-H07155188-A | NITRO REDUCTASE GENE | CHISSO CORP | 1995-06-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10888549-B2 | Pharmaceutical agents targeting cancer stem cells | YAP1, RUNX1, GLI1 | ACE 4595/4885CHRM2 4781/4885ADRA2A 3143/4885 |
| US-20190091202-A1 | PHARMACEUTICAL AGENTS TARGETING CANCER STEM CELLS | YAP1, RUNX1, GLI1 | ACE 4595/4885CHRM2 4781/4885ADRA2A 3143/4885 |
| US-20220184037-A1 | PHARMACEUTICAL AGENTS TARGETING CANCER STEM CELLS | YAP1, RUNX1, GLI1 | ACE 4595/4885CHRM2 4781/4885ADRA2A 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.